Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OPI-001
- Development stage
- Preclinical
- Lead developer
- Otologic Pharmaceutics
- Modality
- Small Molecules
01
Overview
OPI-001 is a small molecule drug in preclinical development for the treatment of acute and chronic hearing loss, specifically targeting sensorineural hearing loss. The drug aims to regenerate sensory hair cells in the inner ear, which are critical for auditory function. OPI-001 was initially developed by Hough Ear Institute and is currently being advanced by Otologic Pharmaceutics. The program has received funding from the Department of Defense to support further preclinical research and development[1][3]. Its mechanism of action is not explicitly detailed in public sources but centers on promoting regeneration or protection of cochlear hair cells.
Beyond the preview
Go deeper on OPI-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OPI-001.